All You Need To Know About The Biological E. Vaccine Candidate

Sputnik Light ,Delayed Second Pfizer COVID-19 Shot, Pfizer Vaccine, rare COVID vaccine side-effects, Biological E. Vaccine Candidate, valneva vaccine, woman hates needles , Pfizer Donates DrugsVaccination for pregnant women ,COVAXIN ,COVID-19 reinfection ,co-win ,vaccine registration ,COVID-19 Vaccine For Below 18 Years, Free COVID-19 Vaccination ,Covishield Vaccine Open Market Price, Free COVID-19 vaccine ,COVID19 Vaccination Phase 3 ,18 years above eligible ,Priority Vaccines For Journalists ,Sputnik V Vaccine ,anti-rabies vaccine ,double shots of covid-19 vaccine ,100-Year-Old Woman vaccinated ,Bollywood stars COVID-19 vaccine ,Germany suspends AstraZeneca, After effects of COVID-19 infection ,Oxford Vaccine Europe Ban, Johnson Vaccine
Biological E. Vaccine Candidate: Amidst the huge surge in COVID-19 cases, the Indian vaccine making company Biological E. is gearing up to churn out about 75 to 80 million doses per month of its recombinant protein vaccine candidate which is in the third phase of its clinical trials.

The vaccine is expected to be rolled out in the market from August this year. The company has also said that it will be one of the most affordable vaccines in the country.

The managing director of Biological E Mahima Datla said that they are focusing on hunkering down and getting the vaccines through to the finish line to make sure that they are able to deliver capacities.

The rollout of the vaccine could help ease the vaccine crunch that the country is currently going through.

Here’s all we know about Biological E’s subunit vaccine candidate.

– The Indian vaccine company Biological E. is launching Phase 3 of its clinical trials of its COVID-19 subunit vaccine candidate after it obtained the approval of the Central Drugs Standard Control Organisation’s (CDSCO) Subject Expert Committee (SEC).

– The vaccine candidate contains an antigen which is developed by the Texas Children’s Hospital Center for Vaccine Development.

– According to the company’s managing director Mahima Datla, after the vaccine candidate rolls out in the market, it will be among the most affordable COVID-19 vaccines that you can get a hold of.

– It is in-licensed from Baylor College of Medicine (BCM) ventures integrated commercialisation team.

– The Biological E. vaccine candidate has the combination of Medicago’s Coronavirus Virus-Like particle (CoVLP) with Dynavax’s advanced adjuvant, CpG 1018TM.

– According to Dr Maria Elena Bottazi, who is the associate dean of the National School of Tropical Medicine (NSTM) at BCM the subunit vaccine is modelled after the Hepatitis B vaccine and uses traditional technology.

– She also said that it is cheap to produce at only $ 1.5 per dose, which is approximately Rs 110.

– Phase 3 trials of the vaccine candidate will be carried out at 15 sites across the country in order to analyse the immunogenicity and safety that the vaccine can provide against COVID-19.

– The vaccine is developed for people aged between 18 and 80 years and will enrol approximately 1,268 healthy subjects for the trial.

– The company has already successfully concluded the Phase 1 and 2 trials of the vaccine candidate and it is anticipated to be a part of a larger global Phase 3 study.

– Apart from the protein vaccine, Biological E. has also tied up with Johnson & Johnson for making 600 million doses of the single-dose vaccine in India, developed by the latter.

– The company has been promised funding to produce at least 1 billion doses of COVID-19 vaccines by the end of 2022 under the Quad initiative. It is funded by the US International Development Finance Corporation.